Ogden Christopher (CIK 1914523) reported 9 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-17). Recent activity: Sell CTMX (1,624 shares), Sell CTMX (19,323 shares), Buy CTMX (90,000 shares), Sell CTMX (1,641 shares), Buy CTMX (37,500 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Sell | 1,624 | $4,953 |
| 2026-03-19 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Sell | 19,323 | $124,054 |
| 2026-02-04 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Buy | 90,000 | $0 |
| 2025-06-17 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Sell | 1,641 | $4,841 |
| 2025-06-17 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Buy | 37,500 | $0 |
| 2025-06-17 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Sell | 10,614 | $28,552 |
| 2025-03-20 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Sell | 8,551 | $5,131 |
| 2025-02-06 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Buy | 44,000 | $0 |
| 2025-02-06 | CytomX Therapeutics, Inc. (CTMX) | Chief Financial Officer | Buy | 57,500 | $0 |
Source: SEC Form 4 filings · as of 2026-06-17